Samir Ounzain, HAYA Therapeutics CEO
HAYA Therapeutics gets $65M for 'dark genome' work following last year's Lilly pact
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back with $65 million to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
